Congressman Fred Keller co-sponsors bipartisan plan to reduce prescription drug costs
WASHINGTON (WENY) -- Lower costs, more cures. That's the thinking behind Congressman Fred Keller's new plan to reduce prescription drug costs.
But it's up against an alternative from Speaker Nancy Pelosi, which Democrats are trying to move through the House this week.
"White traveling across Pennsylvania's 12th Congressional District, I have made it a priority to meet with medical professionals and patients to discuss the topic of prescription drug prices," Keller said. "Their suggestions are simple: increase transparency, promote competition, and reform patent laws to allow generics to get to market faster. The Lower Costs, More Cures Act accomplishes those goals."
Keller's H.R.19 is up against H.R.3, which requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain drugs. Specifically, the CMS must negotiate maximum prices for insulin products, and at least 25 single-source, brand-name drugs that do not have generic competition and are among the 125 drugs that account for the greatest national spending. The bill also makes a series of additional changes to Medicare prescription drug coverage and pricing.
According to a press release from Keller's Communications Director, H.R.19, unlike H.R.3, is bipartisan.